Anti-Adalimumab (HUMIRA) ELISA Assay Kit

$1,190.00

The Anti-Adalimumab (HUMIRA) ELISA Assay Kit has been especially developed for the qualitative analysis of antibodies to adalimumab in serum and plasma samples. The Anti-Adalimumab (HUMIRA) ELISA Assay Kit is for research use only and not to be used for diagnostic procedures.

SKU: ADA-QLS-HUM Categories: , ,

Anti-Adalimumab (HUMIRA) ELISA Assay Kit

The Anti-Adalimumab (HUMIRA) ELISA Assay Kit is For Research Use Only

Size: 12 x 8 wells
Sensitivity: +/-
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µL
Alternative Name: Humira

Controls Included


Assay Background

Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface tumor necrosis factor expressing cells in vitro when in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (Tumor necrosis factor- beta). TNF is a naturally occurring cytokine that plays a role in normal inflammatory and immune responses. Increased levels of TNF are found in the joint synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients, and play an imperative role in pathologic inflammation and the joint destruction that are major complications of these diseases. Increased levels of TNF are also measured in psoriasis plaques. In plaque psoriasis, treatment with adalimumab may decrease the epidermal thickness and inflammatory cell infiltration. The relationship between this pharmacodynamics and the mechanism(s) by which adalimumab achieves its clinical effects is not known. Additionally, adalimumab alters biological responses that are induced/regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration during inflammation (ELAM-1, VCAM-1, and ICAM-1 with an ICSO of 1-2 X 10-lOM).

Assay Principle

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Controls and samples (serum or plasma) are incubated in the microtiter plate coated with the drug adalimumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to adalimumab antibodies captured by the drug adalimumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of adalimumab antibodies in the sample or controls. The results can be evaluated with using cut-off value.


Related Products

Adalimumab ELISA Assay Kit
Anti-Bevacuzimab (Avastin) ELISA Assay Kit

Package Inserts


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations